SGLT2 inhibitor

From Food & Medicine Encyclopedia

(Redirected from Gliflozin)

SGLT2 inhibitors or Sodium-glucose co-transporter-2 inhibitors are a class of medications used primarily in the treatment of type 2 diabetes. They work by preventing the kidneys from reabsorbing glucose back into the blood, thereby promoting the excretion of glucose in urine.

Mechanism of Action[edit]

SGLT2 inhibitors work by blocking the sodium-glucose co-transporter-2 (SGLT2), which is responsible for the majority of glucose reabsorption by the kidneys. By inhibiting this transporter, these medications increase the amount of glucose excreted in the urine, thereby lowering blood glucose levels.

Uses[edit]

SGLT2 inhibitors are primarily used in the treatment of type 2 diabetes. They may also be used in the management of heart failure and chronic kidney disease.

Side Effects[edit]

Common side effects of SGLT2 inhibitors include urinary tract infections, yeast infections, and increased urination. Rare but serious side effects may include ketoacidosis and kidney injury.

Examples[edit]

Examples of SGLT2 inhibitors include canagliflozin, dapagliflozin, and empagliflozin.

See Also[edit]

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.